Chemical Nametrilaciclib
Dosage FormInjection (intravenous; 300 mg)
Drug ClassKinase inhibitors
CompanyG1 Therapeutics
Approval Year2021


  • Indicated to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive-stage small cell lung cancer
Last updated on 3/14/2022

More on this drug: Clinical Trials

Document TitleYearSource
Cosela (trilaciclib) Prescribing Information. 2021G1 Therapeutics, Inc. Durham, NC

Have we missed a study, or would you like to comment on a study?